174 related articles for article (PubMed ID: 35984529)
1. A pilot study of
Wang G; Zhou M; Zang J; Jiang Y; Chen X; Zhu Z; Chen X
EJNMMI Res; 2022 Aug; 12(1):52. PubMed ID: 35984529
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
4. Baseline [
Groener D; Schneider S; Baumgarten J; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Wichert J; Mandel P; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672421
[TBL] [Abstract][Full Text] [Related]
5. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
6. Impact of [
Groener D; Wichert J; Adams M; Mader N; Klimek K; Nguyen Ngoc C; Baumgarten J; Happel C; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568694
[TBL] [Abstract][Full Text] [Related]
7. Neuron-specific enolase has potential value as a biomarker for [
Rosar F; Ribbat K; Ries M; Linxweiler J; Bartholomä M; Maus S; Schreckenberger M; Ezziddin S; Khreish F
EJNMMI Res; 2020 May; 10(1):52. PubMed ID: 32449086
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of [
Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
[TBL] [Abstract][Full Text] [Related]
9.
van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
[No Abstract] [Full Text] [Related]
10. Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
Burgard C; Engler J; Blickle A; Bartholomä M; Maus S; Schaefer-Schuler A; Khreish F; Ezziddin S; Rosar F
Front Med (Lausanne); 2023; 10():1339160. PubMed ID: 38298510
[TBL] [Abstract][Full Text] [Related]
11. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.
Alberts I; Schepers R; Zeimpekis K; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):951-956. PubMed ID: 36136102
[TBL] [Abstract][Full Text] [Related]
12.
Kesler M; Levine C; Hershkovitz D; Mishani E; Menachem Y; Lerman H; Zohar Y; Shibolet O; Even-Sapir E
J Nucl Med; 2019 Feb; 60(2):185-191. PubMed ID: 30002112
[No Abstract] [Full Text] [Related]
13. Glucose Metabolism Modification Induced by Radioligand Therapy with [
Urso L; Panareo S; Castello A; Ambrosio MR; Zatelli MC; Caracciolo M; Tonini E; Valpiani G; Boschi A; Uccelli L; Cittanti C; Bartolomei M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297443
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
15.
Gündoğan C; Ergül N; Çakır MS; Kılıçkesmez Ö; Gürsu RU; Aksoy T; Çermik TF
Mol Imaging Radionucl Ther; 2021 Jun; 30(2):79-85. PubMed ID: 34082503
[TBL] [Abstract][Full Text] [Related]
16. Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer.
Zhou X; Li Y; Jiang X; Wang X; Chen S; Shen T; You J; Lu H; Liao H; Li Z; Cheng Z
Front Oncol; 2020; 10():585213. PubMed ID: 33604285
[TBL] [Abstract][Full Text] [Related]
17. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
18. Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [
Hartrampf PE; Lapa C; Serfling SE; Buck AK; Seitz AK; Meyer PT; Ruf J; Michalski K
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503080
[TBL] [Abstract][Full Text] [Related]
19. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparisons of
Lin BH; Chen SH; Chen SM; Qiu QR; Gao RC; Wei Y; Zheng QS; Miao WB; Xu N
Int Urol Nephrol; 2023 Nov; 55(11):2753-2764. PubMed ID: 37477778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
